Form 4: Processa CDO Sian Bigora Awarded Equity Compensation

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, was granted 96,000 Restricted Stock Units and 288,000 stock options.

Summary

• Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), acquired 96,000 Restricted Stock Units (RSUs) on October 1, 2025.
• Sian Bigora also acquired 288,000 Stock Options (right to buy) on October 1, 2025, with an exercise price of $0.198 per share.
• The Restricted Stock Units vest one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
• The Stock Options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is a standard practice for executive compensation, aligning the executive's interests with long-term shareholder value. It reflects ongoing commitment and retention, which is generally positive for corporate governance and stability.

Positives

• The grant of equity awards aligns the Chief Development Officer's interests with long-term shareholder value.
• Equity compensation is a standard practice for executive retention and motivation.

Future Outlook

The vesting schedules for the Restricted Stock Units and Stock Options indicate a future increase in Sian Bigora's beneficial ownership of Processa Pharmaceuticals' common stock, contingent on continued employment and performance.

Industry Context

The grant of equity awards to a Chief Development Officer is a common compensation strategy in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align executive interests with shareholder returns.

Comparison to Industry Standards

• Equity compensation, including Restricted Stock Units and stock options, is a standard component of executive pay packages across the biotech and pharmaceutical sectors, comparable to practices at companies like Pfizer, Moderna, or Johnson & Johnson, though the specific quantities and vesting schedules vary based on company size, executive role, and compensation philosophy.

Stakeholder Impact

• Shareholders: Potential for future dilution upon the vesting and exercise of these equity awards, balanced by improved alignment of management incentives with long-term company performance.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Vesting of 96,000 Restricted Stock Units, with one-third vesting on October 1, 2026, and the remainder monthly until October 1, 2028.
• Vesting of 288,000 Stock Options, with one-third vesting on October 1, 2026, and the remainder ratably over the subsequent two years.

Key Dates

Recommendation

This Form 4 reports a routine grant of equity compensation to a key executive, which is a standard practice for aligning management incentives. It does not provide new operational or financial performance data that would significantly alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Processa Pharmaceuticals, PCSA, Sian Bigora, Restricted Stock Units, Stock Options, Equity Award, Insider Transaction, Executive Compensation